VF
ADMS

Virtu Financial’s Adamas Pharmaceuticals ADMS Stock Holding History

Virtu Financial’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-24,641
Closed -$102K – 1947
2020
Q3 		$102K Buy
+24,641
New +$95.3K 0.02% 714
2019
Q4 		$275K Buy
+72,587
New +$347K 0.03% 736

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Virtu Financial's ADMS Position: Q4 2020 in Review

Virtu Financial sold out of Adamas Pharmaceuticals (ADMS) in Q4 2020, closing a stake of 24,641 shares — an estimated $102K sold.

Virtu Financial first reported a position in ADMS in Q4 2019 and held it in 2 quarters. The position peaked at $275K in Q4 2019. 65 funds tracked by Wall St. Rank hold ADMS as of Q4 2020.

  • Virtu Financial reported no remaining Adamas Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Virtu Financial sold 24,641 Adamas Pharmaceuticals shares in Q4 2020, an estimated $102K.
  • Virtu Financial first reported a position in Adamas Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Virtu Financial's Adamas Pharmaceuticals position peaked at $275K in Q4 2019.
  • 65 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2020.

Based on Virtu Financial's 13F filing for Q4 2020, filed 24 Feb 2021.